No Data
No Data
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $19
Express News | Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
Is Syndax Pharmaceuticals (NASDAQ:SNDX) A Risky Investment?
Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $41